Olav Zilian
Analyst-Equity chez Banque Pictet & Cie SA
Profil
Olav Zilian is currently a Senior Equity Analyst & Portfolio Manager at Banque Pictet & Cie SA since 2021.
Prior to this, he worked as a Senior Healthcare Analyst at Mirabaud Securities Ltd.
(Switzerland) from 2018 to 2021.
He also served as a Senior Vice President-Corporate Development at MediGene AG in 2016-2017.
Dr. Zilian worked as an Analyst at Baader Helvea AG and MIRSEC Partners LLP (Switzerland).
He was a Professor at Swiss Institute For Experimental Cancer Research.
Dr. Zilian holds a doctorate degree from the University of Basel and the University of Zurich.
He also has an MBA from the International Institute for Management Development.
Postes actifs de Olav Zilian
| Sociétés | Poste | Début |
|---|---|---|
Banque Pictet & Cie SA
 Banque Pictet & Cie SA Investment ManagersFinance Banque Pictet & Cie SA is an independent Swiss private bank which specializes in asset and wealth management. Headquartered in Geneva, the firm was founded in 1805 to manage the wealth of private and institutional investors. They do not engage in investment banking and do not issue commercial, mortgage or unsecured loans. | Analyst-Equity | 01/06/2021 |
Anciens postes connus de Olav Zilian
| Sociétés | Poste | Fin |
|---|---|---|
| Mirabaud Securities Ltd. (Switzerland) | Analyst-Equity | 01/04/2021 |
| MEDIGENE AG | Corporate Officer/Principal | 01/12/2017 |
| MIRSEC Partners LLP (Switzerland) | Analyst-Equity | - |
| Swiss Institute For Experimental Cancer Research | Corporate Officer/Principal | - |
Baader Helvea AG
 Baader Helvea AG Investment Banks/BrokersFinance Baader Helvea AG (Baader Helvea) s the research-based Swiss brokerage subsidiary of Baader Bank AG (XE: BWB) in Germany. Formerly known as Helvea SA, established in 1990, the firm is located in Geneva and specializes in equity research, sales, sales trading, execution and administration, and services institutional clients worldwide, including pension funds, insurance funds, unit trusts, balanced funds and hedge funds. Their core market is Switzerland with a focus on small- and mid-cap companies; however, they also have expertise in European equity especially in those sectors in which Swiss companies operate as global players, such as banking, insurance, healthcare, food manufacturing, chemicals and luxury goods. The firm's research process focuses on company analysis and includes a company visitation program. They aim to identify companies likely to generate superior returns for shareholders and to evaluate sector or company-specific trends. | Analyst-Equity | - |
Formation de Olav Zilian
| University of Basel | Doctorate Degree |
| University of Zurich | Doctorate Degree |
| International Institute for Management Development | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEDIGENE AG | Health Technology |
| Entreprise privées | 5 |
|---|---|
Banque Pictet & Cie SA
Banque Pictet & Cie SA Investment ManagersFinance Banque Pictet & Cie SA is an independent Swiss private bank which specializes in asset and wealth management. Headquartered in Geneva, the firm was founded in 1805 to manage the wealth of private and institutional investors. They do not engage in investment banking and do not issue commercial, mortgage or unsecured loans. | Finance |
Baader Helvea AG
Baader Helvea AG Investment Banks/BrokersFinance Baader Helvea AG (Baader Helvea) s the research-based Swiss brokerage subsidiary of Baader Bank AG (XE: BWB) in Germany. Formerly known as Helvea SA, established in 1990, the firm is located in Geneva and specializes in equity research, sales, sales trading, execution and administration, and services institutional clients worldwide, including pension funds, insurance funds, unit trusts, balanced funds and hedge funds. Their core market is Switzerland with a focus on small- and mid-cap companies; however, they also have expertise in European equity especially in those sectors in which Swiss companies operate as global players, such as banking, insurance, healthcare, food manufacturing, chemicals and luxury goods. The firm's research process focuses on company analysis and includes a company visitation program. They aim to identify companies likely to generate superior returns for shareholders and to evaluate sector or company-specific trends. | Finance |
| Swiss Institute For Experimental Cancer Research | |
| Mirabaud Securities Ltd. (Switzerland) | Finance |
| MIRSEC Partners LLP (Switzerland) | Finance |
